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Abstract
We here present the study results of 21 HIV-1 infected 
children who were treated with indinavir plus low-dose 
ritonavir and two nucleoside reverse transcriptase inhibitors 
(NRTIs) for 48 weeks. Although this q12h HAART regimen 
had potent antiretroviral activity, it was frequently 
associated with side effects and discontinuation of therapy.
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Introduction
Indinavir is a potent protease inhibitor (PI), which has 
successfully been used in adults and children in combination with 
nucleoside reverse transcriptase inhibitors (NRTIs) to suppress 
HIV-1 infection [1, 2]. Durable suppression of HIV requires 
good adherence to the HAART regimen. Discontinuation or 
irregular use of HAART results in viral rebound, resistance 
of HIV to the medication and ultimately AIDS [3]. HAART 
regimens containing indinavir are difficult to adhere to. Indina-
vir, when used as a sole PI, must be administered three times 
daily (q8h), thus interfering with the sleeping time and school 
hours of children. In addition, food restrictions further compli-
cate the regimen, since the drug needs to be taken on an empty 
stomach or with a low-caloric meal. 
To ensure adherence to an indinavir-containing HAART 
regimen, less frequent and less complicated dosing schemes 
are required. An addition of low-dose ritonavir to indinavir 
increases plasma levels of indinavir allowing for a twice-daily 
medication scheme without the necessity for food restric-
tions [4, 5]. Currently, no information on the long-term clinical 
efficacy and safety of this combination in children is available. 
Therefore, we performed an open uncontrolled pilot study in 
21 HIV-1 infected children who were treated with indinavir 
and low-dose ritonavir containing HAART. 
Methods
Children included in the Rotterdam cohort and treated with 
q8h-dosed HAART with indinavir as the sole PI were offered 
to change therapy to q12h-dosed HAART with indinavir and 
low-dose ritonavir [6]. In addition, between 2001 and 2002, 
HAART-containing indinavir and low-dose ritonavir were initi-
ated in children naive to antiretroviral medication with a mean 
HIV RNA level > 5.000 copies/ml and a CD4+ T-cell count below 
age-specific reference values. The study protocol was approved by 
the medical ethical committee of the Erasmus MC. Written and 
informed consent was obtained from parents and patients. The 
patients’ medical histories, physical examinations and laboratory 
values were analyzed before the start of the medication and after 
4, 8, 12, 24, 36 and 48 weeks of treatment. After minimally 2 weeks 
of treatment, the steady-state pharmacokinetics of indinavir was 
determined [7]. This procedure was repeated when dosage adjust-
ment of indinavir was necessary to normalize the area under the 
plasma concentration–time curve (AUC) to adult values. 
Age-specific reference values for the CD4+  T-cells were 
calculated by dividing the patient’s individual value at the differ-
ent time points by the median of the reference value at the dif-
ferent time points [8]. Differences between paired variables were 
analyzed with the Wilcoxon-signed rank test and between groups 
with the Mann-Whitney U-test. For statistical analysis of the data, 
SPSS©12 and Microsoft Excel©97 software were used.
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Results
A total of 21 children were enrolled in the study of which 
16 completed the 48 weeks study period. The baseline char-
acteristics of all patients are summarized in table 1. Four 
children were naive to antiretroviral therapy (Group A). 
Seventeen children had received prior indinavir-contain-
ing HAART for a median period of 18 months (range, 
2–50 months). Of these, nine had baseline HIV-1 RNA lev-
els below 500 copies/ml (Group B1) and eight had HIV-1 
RNA levels above 500 copies/ml (Group B2). Indinavir was 
started at a median dosage of 400 mg/m2 (range 300–600) 
and ritonavir was started at a median dosage of 125 mg/m2 
(range 100–125). 
The clinical condition of the patients during the study 
period was good. None of the patients showed signs and 
symptoms of AIDS and no progression in their CDC-clas-
sification stage was observed. The course of the surrogate 
markers viral load and CD4 + T-cell counts during the fol-
low-up are depicted in table 2. Overall after 48 weeks of 
treatment 13 out of the 16 children still on treatment had 
HIV-1 RNA levels < 500 copies/ml and 11 < 50 copies/ml. 
In Group A, three out of four patients had HIV-1 RNA 
levels < 50 copies after 48 weeks of treatment. In Group 
B1, seven out of eight patients had HIV-1 RNA levels < 50 
copies. In Group B2, three of four children had HIV-1 RNA 
levels < 500 copies/ml, but only 1 had HIV-1 RNA levels 
< 50 copies/ml. Over time an increase in CD4 + T-cells was 
observed, albeit not significant for any treatment group. 
(p-value baseline vs week 48 for the total group CD4% 
total T-cells 0.234 and for CD4% normal 0.14). 
Most children (n = 19) reported side effects related 
to the medication. The adverse events occurred through-
out the entire study period. These side effects were of-
ten mild and of gastrointestinal origin. However, serious 
adverse were reported in seven children. These included 
nephrolithiasis (n = 2), silent nephrolithiasis found upon 
ultrasound research (n = 2), jaundice (n = 1), impaired 
liver functions, vomiting and malaise (n = 1) and dehy-
dration due to vomiting (n = 1). Serious side effects were 
observed in all study groups (Group A: 1, Group B1: 3 and 
B2: 3) (Table 3).
Five patients stopped therapy during the follow-up period. 
In one additional patient medication was discontinued on the 
last study day. Discontinuation happened four times because 
of drug toxicity (1 nephrolithiasis, 1 silent nephrolithiasis, 1 
rash, 1 hepatitis) and twice on patient request. All children 
that stopped medication were pretreated and most (n = 4) 
had detectable viral loads at the start of the study. These 
patients had suffered from indinavir related toxicity in the 
past. However, none of the adverse events that had occurred 
before the start of the study were serious (Table 4). 
No significant differences were found between the PK 
parameters of children with or without side effects (data 
not shown). However, in two children renal side effects 
resolved after a decrease of the indinavir or ritonavir dosage. 
In the four children who discontinued medication because 
of side effects dosage adjustments were not performed. 
This was because of the seriousness of the side effects 
and hesitation in the patients and their parents to restart 
indinavir.
Discussion
The studied regimen had potent antiretroviral activity with 
suppression of HIV in most children who remained on ther-
apy for 1 year. However, side effects occurred frequently. 
No clear relation between the height of PK parameters 
and side effects or discontinuation of therapy were found. 
Still, most children in our study received indinavir/ritonavir 
400/125 mg/m2 q12h which has been shown to result in sig-
nificantly higher indinavir exposure compared to reference 
data of indinavir q8h in both adults and children [7]. This 
increased AUC may result in a higher incidence of side 
effects, especially when instructions to increase fluid in-
take are not sufficiently followed. This is of major concern 
since the occurrence of side effects poses a major threat to 
the adherence, whilst maintenance of adherence was the 
Table 1 
Baseline characteristics of the 21 children.
Characteristics:
Sex (male/female) 7/14
Ethnicity (white/non-white) 2/19
Age in yearsa 7 (0.4–16.3)
Route of infection:
Vertical 15
Blood products  3
Unknown 3
CDC classificationc:
N1: 1; N2: 3; N3: 2
A1: –; A2: 3; A3: 3
B1: –; B2: 5; B3: –
C1: –; C2: 2; C3: 2
Treatment history:
Naïve to HAART (Group A) 4
Pretreated with PI containing 
HAART, HIV RNA < 500 copies/ml 
(Group B1)
9
Pretreated with PI-containing 
HAART, HIV RNA > 500 copies/ml 
(Group B2)
8
Baseline HIV-1 RNA levelsb (copies/ml):
Group A  168,750 (48,975–589,500)
Group B2  4,650 (2,360–14,794)
PI dosageb:
Indinavir (mg/m2) 400  (300–600)
Ritonavir (mg/m2) 125  (100–125)
NRTI backbone:
AZT/3TC, q12h 20
ddI/d4T, 12h 1
a Median (range); b Median interquartile range (IQR); c CDC 
classification as defined by the US Centers for Disease Control, 
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most important reason to perform this medication change. 
In addition, patients reported that the combination was 
not easy to take: the high pill burden and the bad taste of 
ritonavir liquid were considered as negative aspects of the 
new regimen. Side effects and intolerance to the medica-
tion resulted in a high number of children that discontinued 
the study regimen as compared to studies in children with 
new and easier to use HAART regimens. In a study on 
lopinavir/ritonavir-containing HAART in children only 2 
out of 100 patients prematurely discontinued treatment [9]. 
However, one should be cautious to compare both studies, 
since the numbers of patients are relatively small and the 
studied patient population selected differently. Interest-
ingly, a large proportion of children that discontinued med-
ication in our study had detectable viral loads at baseline. 
Possibly, preexisting problems with adherence may have 
influenced our data: As a result of non-adherence plasma 
levels tent to fluctuate, which may induce side effects [10]. 
In addition non-adherent patients are more likely to be 
less motivated to continue medication and thus terminate 
study participation. 
Because of the high number of side effects and patients 
that prematurely discontinued medication, we feel that newer 
and easier to use HAART regimens than indinavir/low-dose 
ritonavir should be used to treat HIV-1 infected children. 
However when these are not available indinavir combined 
Table 2 
Clinical en immunological parameters during 1-year follow-up of 21 children treated with indinavir/ritonavir.
Week 0 Week 12 Week 24 Week 36 Week 48
Total Group:
On treatment  21 18 16 16 16
HIV-1 RNA levels < 500  9 (43%) 13 (72%) 13 (81%) 14 (88%) 13 (81%)
HIV-1 RNA levels < 50  6 (29%)  8 (44%) 10 (63%) 11 (69%) 11 (69%))
Median %CD4a 37 (23–54) 40 (32-61) 41 (35–61) 40 (32–62) 40 (30-62)
Median CD4% normala 61 (38–105) 72 (47–117) 78 (55–122) 67 (57–135) 68 (54–128)
Group A: 
On treatment  4  4  4  4  4
HIV-1 RNA levels < 500  0  3 (75%)  4 (100%)  3 (75%)  3 (75%)
HIV-1 RNA levels < 50  0  1 (25%)  2 (50%)  3 (75%)  3 (75%)
Median %CD4  a 28 (7–41) 39 (15–46) 38 (26–58) 36 (21–56) 40 (26–58)
Median CD4% normala  39 (8–123) 45 (27–95) 71 (42–149) 61 (49–115) 57 (42–139)
Group B1:
On treatment  9  8  8  8  8
HIV-1 RNA levels < 500  9 (100%)  6 (75%)  8 (100%)  8 (100%)  7 (88%)
HIV-1 RNA levels < 50  6 (67%)  6 (75%)  8 (100%)  6 (75%)  7 (88%)
Median %CD4a 45 (38–48) 46 (38–59) 43 (37–53) 42 (37–57) 40 (32–56)
Median CD4% normala  96 (60–118) 76 (69–134) 78 (67–126) 87 (58–141) 80 (57–121)
Group B2: 
On treatment  8  7  4  4  4
HIV-1 RNA levels < 500  0  4 (75%)  1 (25%)  3 (75%)  3 (75%)
HIV-1 RNA levels < 50  0  1 (15%)  0  2 (50%)  1 (25%)
Median %CD4a 24 (19–46) 33 (29–61) 34 (22–53)  40 (27–53) 41 (25–52)
Median CD4% normala 53 (27–68) 69 (51–124) 83 (48–122) 100 (54–143) 90 (49–205)
a Median (interquartile range). Group A: children naive to HAART, Group B1: PI experienced patients with HIV-1; RNA < 500 copies on 
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with ritonavir can be considered as a treatment option for 
HIV-1 infected children.
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Table 3 
No significant difference in the occurrence of SAE's between 
the three treatment groups: NPar tests occurrence of SAE’s
 χ 2-test frequencies.
Observed N Expected N Residual
Group A
SAE 1 2.0   1.0
No SAE 3 2.0 1.0
Total 4
Group B1
SAE 3 4.5   1.5
No SAE 6 4.5 1.5
Total 9
Group B2
SAE 3 4.0   1.0
No SAE 5 4.0 1.0
Total 8
Test statistics Group A Group B1 Group B2
χ2 a,b 1.000 1.000 0.500
Df 1 1 1
Asymp. Sig. 0.317 0.317 0.480
a 2 cells (100.0%) have expected frequencies less than 5. The 
minimum expected cell frequency is 2.0; b 2 cells (100.0%) have 
expected frequencies less than 5. The minimum expected cell fre-
quency is 4.5; c 2 cells (100.0%) have expected frequencies less 
than 5. The minimum expected cell frequency is 4.0
Table 4 
Study termination and viral load at start of the study: NPar 
tests χ 2-test frequencies.
Observed N Expected N Residual
Group B1
Terminated study 
medication
2 4.5   2.5
Did not terminate 
study medication
7 4.8 2.5
Total 9
Group B2
Terminated study 
medication
4 4.0 0.0
Did not terminate 
study medication
4 4.0 0.0
Total 8
Test statistics Group B1 Group B2
χ2 a,b 2.778 0.000
Df 1 1
Asymp. Sig. 0.096 1.000
a 2 cells (100.0%) have expected frequencies less than 5. The mini-
mum expected cell frequency is 4.5; b 2 cells (100.0%) have expected 
frequencies less than 5. The minimum expected cell frequency is 4.0